Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 408
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03655353 | A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer | ||
| NCT04947605 | Epidemiological Landscape of Cervical Cancer in Latin America | ||
| NCT01015339 | Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | ||
| NCT01729481 | Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer | ||
| NCT01996267 | Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 | ||
| NCT04920981 | Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC | ||
| NCT04363853 | Tocilizumab Treatment in Patients With COVID-19 | ||
| NCT01565200 | HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 | ||
| NCT00275132 | Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | ||
| NCT01428414 | Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer | ||
| NCT01208896 | Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma | ||
| NCT01249638 | Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC | ||
| NCT00477048 | Efficacy and Safety of SQV in Patients Who Have Chronic IDV Nephrotoxicity | ||
| NCT01709097 | Compliance/Adherence After Kidney Transplant, With or With Out Med-O-Wheel™. | ||
| NCT00815867 | Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant | ||
| NCT03548428 | Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) | ||
| NCT00193609 | Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site | ||
| NCT03961698 | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma | ||
| NCT01458730 | Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | ||
| NCT00645606 | Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia | ||
| NCT05918666 | National Register of Actionable Mutations | ||
| NCT02383290 | The Implementation of Pharmacogenomics Into Primary Care in British Columbia | ||
| NCT00112931 | Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | ||
| NCT01640405 | Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells | ||
| NCT05007613 | Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | ||
| NCT06068985 | Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade | ||
| NCT01523340 | A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response | ||
| NCT01196455 | Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer | ||
| NCT04462276 | Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease | ||
| NCT05651724 | Global Research Initiative for Patients Screening on MASH | ||
| NCT04059887 | Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY] | ||
| NCT01368848 | Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC) | ||
| NCT00400738 | The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected Patients | ||
| NCT03301493 | Genomic Testing and Resulting Medical Decisions | ||
| NCT01828736 | Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma | ||
| NCT03911219 | Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy | ||
| NCT02303119 | Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) | ||
| NCT00938444 | Evaluation of the BRADA and ABILHAND Questionnaires | ||
| NCT01259856 | Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) | ||
| NCT01697267 | Rituximab Vasculitis Maintenance Study | ||
| NCT04671693 | A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. | ||
| NCT00620269 | Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III | ||
| NCT04702256 | Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF | ||
| NCT02344472 | Detect V / CHEVENDO (Chemo vs. Endo) | ||
| NCT00203606 | Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C | ||
| NCT03590535 | 5th Generation cTnT in ED ACS | ||
| NCT03831490 | Study for Improving Maternal, Pregnancy and Child Outcomes | ||
| NCT01259817 | Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) | ||
| NCT00626197 | A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) | ||
| NCT00216086 | Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer |
